Market Closed - Nasdaq Stockholm 11:29:49 2024-04-24 am EDT 5-day change 1st Jan Change
9.22 SEK +0.22% Intraday chart for OssDsign AB -4.16% +15.25%
Sales 2023 112M 10.29M Sales 2024 * 127M 11.68M Capitalization 898M 82.44M
Net income 2023 -130M -11.93M Net income 2024 * -59M -5.41M EV / Sales 2023 5.54 x
Net cash position 2023 160M 14.7M Net cash position 2024 * 96.68M 8.87M EV / Sales 2024 * 6.3 x
P/E ratio 2023
-5 x
P/E ratio 2024 *
-15 x
Employees 41
Yield 2023 *
-
Yield 2024 *
-
Free-Float 50.84%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.22%
1 week-4.16%
Current month-8.71%
1 month-11.35%
3 months-2.95%
6 months+53.67%
Current year+15.25%
More quotes
1 week
9.10
Extreme 9.1
9.85
1 month
9.10
Extreme 9.1
10.94
Current year
7.78
Extreme 7.78
10.94
1 year
4.53
Extreme 4.53
10.94
3 years
2.61
Extreme 2.605
10.94
5 years
2.61
Extreme 2.605
26.80
10 years
2.61
Extreme 2.605
26.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 20-08-31
Director of Finance/CFO 61 19-12-31
Chief Operating Officer 51 15-12-31
Members of the board TitleAgeSince
Chairman 64 16-04-19
Director/Board Member 59 14-12-31
Director/Board Member 60 18-12-31
More insiders
Date Price Change Volume
24-04-24 9.22 +0.22% 116 366
24-04-23 9.2 -1.50% 311,684
24-04-22 9.34 -1.37% 156,756
24-04-19 9.47 -1.56% 124,226
24-04-18 9.62 0.00% 108,405

Delayed Quote Nasdaq Stockholm, April 24, 2024 at 11:29 am EDT

More quotes
OssDsign AB, formerly known as Oss-Q AB is a Sweden-based orthopedic medical device company. It aims at developing implantable products that respond to clinical challenges, with focus on bone healing. Its primary focus is skull surgery. The Company uses design solutions, material compositions and manufacturing processes mainly based on proprietary bioceramic technologies. The bioceramics it uses integrate with tissues and support bone ingrowth. OssDsign AB's main product is Craniomosaic, an implant for the repair of skull defects (cranioplasty). Along with it, the Company develops bioceramic implants for facial bone augmentation. The Company's customers include neurosurgeons, craniofacial and maxillofacial surgeons.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings